References
- Alberio L, Safa O, Clemetson KJ, Esmon CT, Dale GL. Surface expression and functional characterization of alpha-granule factor V in human platelets: Effects of ionophore A23187, thrombin, collagen and convulxin. Blood 2000; 95: 1694–1702
- Dale GL, Friese P, Batar P, Hamilton SF, Reed GL, Jackson KW, Clemetson KJ, Alberio L. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature 2002; 415: 175–179
- Szasz R, Dale GL. COAT-platelets. Current Opinion Hematol 2003; 10: 351–355
- Remenyi G, Szasz R, Friese P, Dale GL. Role of mitochondrial permeability transition pore in coated-platelet formation. Arterioscler Thromb Vasc Biol 2005; 25: 467–471
- Dale GL. Coated-platelets: An emerging component of the procoagulant response. J Thromb Haemostasis 2005; 3: 2185–2192
- Dale GL, Remenyi G, Friese P. Quantitation of microparticles released from coated-platelets. J Thromb Haemostasis 2005; 3: 2081–2088
- Hemler ME. Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. Ann Rev Cell Develop Biol 2003; 19: 397–422
- Parise LV, Smyth SS, Coller BS. Platelet morphology, biochemistry and function. Williams Hematology, E Beutler, MA Lichtman, BS Coller, TJ Kipps, U Seligsohn. McGraw-Hill, New York 2001; 1357–1408
- Clay D, Rubinstein E, Mishal Z, Anjo A, Prenant M, Jasmin C, Boucheix C, Bousse-Kerdiles MC. CD9 and megakaryocyte differentiation. Blood 2001; 97: 1982–1989
- Worthington RE, Carroll RC, Boucheix C. Platelet activation by CD9 monoclonal antibodies is mediated by the Fc gamma II receptor. Br J Haematol 1990; 74: 216–222
- Brisson C, Azorsa DO, Jennings LK, Moog S, Cazenave JP, Lanza F. Co-localization of CD9 and GPIIb-IIIa (alpha IIb beta 3 integrin) on activated platelet pseudopods and alpha-granule membranes. Histochem J 1997; 29: 153–165
- Mangin PH, Kleitz L, Boucheix C, Gachet C, Lanza F. CD9 negatively regulates integrin alpha(llb)beta(3) activation and could thus prevent excessive platelet recruitment at sites of vascular injury. J Thromb Haemost 2009; 7: 900–902
- Miyado K, Yamada G, Yamada S, Hasuwa H, Nakamura Y, Ryu F, Suzuki K, Kosai K, Inoue K, Ogura A, et al. Requirement of CD9 on the egg plasma membrane for fertilization. Science 2000; 287: 321–324
- Boucheix C, Rubinstein E. Tetraspanins. Cell Mol Life Sci 2001; 58: 1189–1205
- Higginbottom A, Takahashi Y, Bolling L, Coonrod SA, White JM, Partridge LJ, Monk PN. Structural requirements for the inhibitory action of the CD9 large extracellular domain in sperm/oocyte binding and fusion. Biochem Biophys Res Commun 2003; 311: 208–214
- Schmid E, Zurbriggen A, Gassen U, Rima B, ter Meulen V, Schneider-Schaulies J. Antibodies to CD9, a tetraspan transmembrane protein, inhibit canine distemper virus-induced cell-cell fusion but not virus-cell fusion. J Virol 2000; 74: 7554–7561
- Batar P, Dale GL. Simultaneous engagement of thrombin and Fc-gamma-RIIA receptors results in platelets expressing high levels of procoagulant proteins. J Lab Clin Med 2001; 138: 393–402
- Jobe SM, Leo L, Eastvold JS, Dickneite G, Ratliff TL, Lentz SR, Di PJ. Role of FcR-gamma and factor XIIIA in coated platelet formation. Blood 2005; 106: 4146–4151
- Stipp CS, Kolesnikova TV, Hemler ME. Functional domains in tetraspanin proteins. Trends Biochem Sci 2003; 28: 106–112
- Hamilton SF, Miller MW, Thompson CA, Dale GL. Glycoprotein IIb/IIIa inhibitors increase COAT-platelet production in vitro. J Lab Clin Med 2004; 143: 320–326
- Tocchetti EV, Flower RL, Lloyd JV. Assessment of in vitro-generated platelet microparticles using a modified flow cytometric strategy. Thromb Res 2001; 103: 47–55
- Jy W, Horstman JJ, Ahn YS. Forum: Measuring circulating cell-derived microparticles. J Thromb Haemostasis 2004; 2: 1842–1851